Patented

Swiss Technology

History

We are a leading research and development organization focused on creating drug delivery system technology solutions that dramatically improve the bioavailability of poorly absorbed ingredients.
LATEST DEVELOPMENT: Learn more about our innovative work in the emerging cannabis industry.

We Are

Pioneering next-generation drug delivery system technologies.

We Believe

Innovation is the driving force for ingredients to perform.

We Create

Solutions that allow leading brands to differentiate themselves.
fulfilling a commitment to sustainable
research and development

Portfolio

Proven Fields of Use
Nutritionals
Pharmaceuticals
Cosmetics
Medical Devices

Novel Solution For Optimizing Cannabinoid Bioavailability

It is well-recognized in the scientific literature that CBD, THC, and other cannabinoids and terpenes, in general, show limited oral bioavailability due to their poor aqueous solubility and extensive first pass metabolism.

To overcome these limitations, a novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology was developed by Vesifact.

The peer-reviewed journal, Molecules, published the results of a double-blind, cross-over pharmacokinetic study in humans where the VESIsorb® formulation showed statistically significant improvements for all measured pharmacokinetic parameters. These results are unmatched in the global marketplace compared to all available published literature.

Unmatched Oral Bioavailability Enhancement of Coenzyme Q10

Coenzyme Q10 plays a key role in mitochondrial energy supply and physiology. Due to its poor aqueous solubility and its relatively high molecular weight, the oral bioavailability of CoQ10 is limited.

To overcome these limitations, a novel self-emulsifying drug delivery system (SEDDS) based upon VESIsorb® technology was developed by Vesifact.

The peer-reviewed journal, Alternative Therapies in Health & Medicine, published a human pharmacokinetic study comparing the VESIsorb® CoQ10 formulation with three marketed "bio-enhanced" CoQ10 formulas. The data of this study as well as a comparison with available published literature shows an unmatched enhancement of CoQ10 bioavailability achieved by the VESIsorb® CoQ10 formulation.

Industry Benchmark For 2-In-1 Omega-3 Fish Oil / CoQ10 Formulation

While CoQ10 has very low aqueous solubility and a relatively high molecular weight, rendering it poorly bioavailable after oral administration, Omega-3 Essential Fatty Acids (EFAs) are known to be heavily food dependent for oral absorption and bioavailability.

To overcome these obstacles, Vesifact developed a novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology, achieving an industry benchmark for unprecedented active loading, improved bioavailability, and mitigating food dependency. Consumer compliance is dramatically improved with fewer capsules needed to achieve optimized therapeutic blood levels.

Human clinical trials have demonstrated the dramatic improvement in oral bioavailability of these two, science-backed ingredients in both well-designed Phase I study (Pharma, Omega-3 EPA) and peer-reviewed published study (Nutritional, CoQ10) by VESIsorb® formulations. Moreover, the food dependency of the VESIsorb® formulation was significantly mitigated.

Innovative Topical Solution For Superior Permeation, Penetration, and Fast-Acting Pain Relief

Established topically applied non-steroidal anti-inflammatory drugs (NSAID) have fallen short to meet the consumer need for fast-acting pain relief with minimal systemic side effects.

To address this unmet medical need, Vesifact developed a novel Diclofenacs solution utilizing a colloidal droplet delivery system based on VESIsorb® technology. 

The results of an in vitro penetration/permeation study using human skin (Franz cell experimental setup) showed that VESIsorb® provided faster and superior delivery of Diclofenac across human skin compared to marketed formulations. The comparator products included the leading brand, Voltaren® (OTC, Emulgel), and the Rx product Pennsaid®, a DMSO-based Diclofenac formulation approved for the topical treatment of osteoarthritic pain.

Fast Acting Oral NSAID For Acute Pain Relief

Ibuprofen, a widely used non-steroidal analgesic drug reaches peak plasma concentrations and maximal analgesic onset only within 1.5 to 2 hours after oral administration. For the treatment of acute pain (e.g., headache), a fast-acting oral dosage form would be highly desired.

To shorten the timeframe between oral administration and onset of action, Vesifact developed a self-emulsifying drug delivery system (SEDDS) based on VESIsorb® technology.

A human clinical study was conducted with the objective to evaluate the pharmacokinetic profile of the Ibuprofen VESIsorb® formulation. The study demonstrated that the time to reach maximum plasma concentration (Tmax) could be reduced from 90 to 35 minutes for a standard oral tablet formulation versus VESIsorb® technology-based capsule formulation.

VESIsorb® Formulated High Potency Omega-3 EPA Improves Bioavailability While Reducing Food Dependency

Treatment of moderate hyperlipidemia with Omega-3 EPA Ethyl Esters requires the medication to be taken with food/fat, which is highly contradicting the general medical advice to reduce fat intake.

To address this marketplace need, Vesifact developed a self-emulsifying drug delivery system (SEDDS) based on VESIsorb® technology to improve the bioavailability and reduce the food/fat dependency of the oral Omega-3 EPA absorption.

The data of a Phase I human pharmacokinetic study showed an 11-fold improvement in bioavailability (AUC) for the VESIsorb® formulation compared to a commercially available Rx brand in the fasted state. Moreover, a dramatically reduced food dependency was observed for the VESIsorb® formulation, whereas the comparator product was highly dependent on food/fat intake for Omega-3 EPA absorption. In conclusion, the VESIsorb® formulation allows the EPA medication to be taken with or without fatty meals.

Proprietary Foam Spray Formulation For Sun Burn Relief

While various studies have confirmed Panthenol's moisturizing and skin barrier enhancement potential, it is well recognized that Panthenol has limited anti-inflammatory effects after dermal application.

To overcome these limitations, Vesifact developed an aqueous colloidal droplet system based on VESIsorb® technology for use in a proprietary fast-breaking foam spray application.

A UV-induced erythema study in humans clearly demonstrated superior efficacy (reduced redness, improved moisturizing, cooling) and, importantly, early onset of action ("fast-acting") of the VESIsorb® formulation compared to the marketed Panthenol ointment (Bepanthen®) and even comparable to the positive control which was an OTC hydrocortisone formulation.

Clinically Proven Sustainable Skin Moisturizer

Skin moisture can principally be improved either by hydrophilic substances binding water on the skin surface (humectants, e.g., glycerol) or by enriching the Natural Moisturizing Factor (NMF) of the skin. There is a significant age-related decline in the levels of NMF.

To supplement the skin with NMF, Vesifact developed a VESIsorb® technology-based liposomal NMF formulation containing a specific triple amino acids complex. 

The VESIsorb® liposomal NMF formulation increased skin moisture significantly and dose-dependently during the two weeks of application. The positive effect of the liposome-delivered NMF on skin moisture surpassed that of the humectant control (hydrogel containing glycerol) and was also noticeable 11 days after termination of the treatment. In contrast, the humectant control showed a rapid drop of skin moisture to values lower than before treatment.

Novel High Performance CBD Topical Solutions Delivered

It has been well established that cannabinoids in topical applications often have poor chemical stability and limited penetration/permeation across human skin.

In response to this unmet marketplace need, Vesifact developed an aqueous colloidal formulation for incorporation into serums, lotions, salves, and foam sprays as well as a self-emulsifying drug delivery system (SEDDS) for a proprietary Dermagel® application both based on VESIsorb® formulation technology.

Successful storage stability data has been established for both VESIsorb® formulations. A human patch test for primary skin irritation and sensitization showed excellent tolerability in all of the 50 panelists of either sex for both formulations. In addition, an in vitro penetration/permeation study using human skin (Franz cell experimental setup) is underway to measure improvements in penetration, permeation, and onset time.

Preservative-Free Eyelid Spray for Dry Eye Relief

Dry eyes affects hundreds of millions of people throughout the world and is one of the most frequent causes of patient visits to eye care practitioners. In almost 80% of patients, a lipid layer disorder of the tear film is observed, causing increased evaporation of water from the aqueous phase of the tear film.

To supplement the lipid layer with polar and non-polar lipids, Vesifact developed a VESIsorb® technology-based colloidal droplet formulation containing phospholipids and triglycerides for spray application onto the eyelid. In addition to the lipids, the formulation contains Ectoin, which by itself was shown to be beneficial for the treatment of dry eyes.

A human clinical study showed that the VESIsorb® formulation was as effective for relieving the discomfort associated with dry eyes as the leading liposomal brand, TearsAgain®. In addition, the VESIsorb® formulation can be sterile-filtered and does not require a preservative, certainly a unique benefit for the treatment of chronic dry eyes.

Proprietary Topical Formulation for Covering and Protection of Scars

Normally healed, inconspicuous scars are usually line-shaped and are flat, pale and soft. In some cases, scarring is associated with pathological processes such as the formation of a bulge. Occlusion, moisturizing, and UV protection of the scar are thought to prevent abnormal scar healing.

To occlude, moisturize, and protect the scar from UV radiation, Vesifact developed a silicone-free VESIsorb® technology-based formulation, which quickly forms an elastic, tack-free, water and rub-off resistant polymer film after application onto the scar. In addition to the polymer providing occlusion, the formulation contains moisturizers (phospholipids, Equol) and UVA/UVB filters.

A clinical study with patients having surgical scars compared the VESIsorb® formulation with one of the market leaders and benchmark product, Kelo-Cote® UV, a silicone-based formulation. For all patients treated with the VESIsorb® formulation, the scars were healed completely or almost completely after three months. Furthermore, the respective skin portion was identical or highly similar to normal skin. In contrast, all patients treated with the benchmark product still had visible scars after three months. Moreover, the VESIsorb® formulation provided excellent UV protection (SPF 50).

Local Treatment of Menopausal Vaginal Discomfort

According to the International Menopausal Society, up to 40% of post-menopausal women are affected by vaginal discomfort caused by declining estrogen levels. The local therapy with hormones is controversial. A non-hormonal treatment based on Equol, a phytoestrogen, might represent an effective treatment option.

For efficient vaginal delivery of Equol, Vesifact developed a self-emulsifying drug delivery system (SEDDS) and a colloidal droplet formulation both based on VESIsorb® formulation technology. The SEDDS formulation was administered within a fast dissolving vaginal capsule, whereas the colloidal droplet formulation was administered as a hydrogel.

To show the benefits of Equol for local treatment of menopausal vulvovaginal atrophy (VVA) a clinical study with post-menopausal women was conducted. According to the study results, treatment with Equol showed overall good efficacy and high acceptance in the patients. Symptoms of VVA, such as vaginal itching, vaginal dryness and pain during intercourse, were reduced and therefore both VESIsorb® formulations may improve the quality of life of menopausal women.

Nutritionals

Omega-3

A pharmacokinetic study comparing omega-3 fish oil using our technology compared to standard omega-3 fish oil demonstrated an increase of 567% in peak blood levels. The relative bioavailability calculated using the area under the curve was also increased by 487%.

Cannabinoids

A pharmacokinetic study (single oral dose, crossover) in humans comparing cannabidiol formulated using our technology to the same cannabidiol in different formulations demonstrated an increase of absorption in peak blood levels. The relative bioavailability of a single oral dose of 25mg of CBD was asserted using the AUC. The results showed xxx% higher bioavailability in our formulation compared to the MCT-based formula.

QH Ubiquinol

A pharmacokinetic study comparing Kaneka QH™ Ubiquinol formulated with our technology to standard Kaneka QH™ Ubiquinol demonstrated an increase of 696% in peak blood levels of Ubiquinol. The relative bioavailability calculated using the area under the curve was also increased by 485%.

Polymethoxylated Flavones (PMF)

In a pharmacokinetic study, we improved the bioavailability of Nobiletin and Tangeretin as well as its metabolites. The relative bioavailability of Nobiletin increased by 288% while the peak plasma levels (Cmax) of Nobiletin, Tangeretin, and their metabolites were increased up to 800%.

Cannabinoids

A pharmacokinetic study (single oral dose, crossover) in humans comparing Cannabidiol (CBD) formulated using our technology to the same Cannabidiol in a different emulsion demonstrated an increase of absorption in peak blood levels. The relative bioavailability of a single oral dose of Cannabidiol was asserted using the AUC. The results showed xxx% higher bioavailability in our formulation compared to the other formula.

And much more ...

VESIsorb® has been successfully applied to more than 50 of the most popular, science-backed ingredients and proprietary formulas like like concentrated omega-3 EFAs, coenzyme Q10, QH ubiquinol Q10, vitamin K2, curcumin, phytocannabinoids, vitamin D, pterostilbene, palm tocotrienols, diindolylmethane (DIM), gamma tocopherols, citrus polymethoxylated flavones (PMFs), resVida®, resveratrol, krill oil, algal DHA, vitamin A (retinoids), phospholipids and beta-caryophyllene, among others.
«
Back
Next
»

Pharmaceuticals

Coenzyme Q10

A pharmacokinetic study (single oral dose, crossover) in humans comparing Coenzyme Q10 formulated using our technology to standard Coenzyme Q10 in different formulations demonstrated an increase of absorption in peak blood levels. The relative bioavailability of a single oral dose of 120mg of Coenzyme Q10 was asserted using the AUC. The results showed 622% higher bioavailability in our formulation compared to the oil-based formula and 499% higher bioavailability compared to the solubilizate.

Omega-3

A pharmacokinetic study comparing omega-3 fish oil using our technology compared to standard omega-3 fish oil demonstrated an increase of 567% in peak blood levels. The relative bioavailability calculated using the area under the curve was also increased by 487%.

QH Ubiquinol

A pharmacokinetic study comparing Kaneka QH™ Ubiquinol formulated with our technology to standard Kaneka QH™ Ubiquinol demonstrated an increase of 696% in peak blood levels of Ubiquinol. The relative bioavailability calculated using the area under the curve was also increased by 485%.

Polymethoxylated Flavones (PMF)

In a pharmacokinetic study, we improved the bioavailability of Nobiletin and Tangeretin as well as its metabolites. The relative bioavailability of Nobiletin increased by 288% while the peak plasma levels (Cmax) of Nobiletin, Tangeretin, and their metabolites were increased up to 800%.

Cannabinoids

A pharmacokinetic study (single oral dose, crossover) in humans comparing Cannabidiol (CBD) formulated using our technology to the same Cannabidiol in a different emulsion demonstrated an increase of absorption in peak blood levels. The relative bioavailability of a single oral dose of Cannabidiol was asserted using the AUC. The results showed xxx% higher bioavailability in our formulation compared to the other formula.

And much more ...

VESIsorb® has been successfully applied to more than 50 of the most popular, science-backed ingredients and proprietary formulas like like concentrated omega-3 EFAs, coenzyme Q10, QH ubiquinol Q10, vitamin K2, curcumin, phytocannabinoids, vitamin D, pterostilbene, palm tocotrienols, diindolylmethane (DIM), gamma tocopherols, citrus polymethoxylated flavones (PMFs), resVida®, resveratrol, krill oil, algal DHA, vitamin A (retinoids), phospholipids and beta-caryophyllene, among others.
«
Back
Next
»

Cosmetics

Coenzyme Q10

A pharmacokinetic study (single oral dose, crossover) in humans comparing Coenzyme Q10 formulated using our technology to standard Coenzyme Q10 in different formulations demonstrated an increase of absorption in peak blood levels. The relative bioavailability of a single oral dose of 120mg of Coenzyme Q10 was asserted using the AUC. The results showed 622% higher bioavailability in our formulation compared to the oil-based formula and 499% higher bioavailability compared to the solubilizate.

Omega-3

A pharmacokinetic study comparing omega-3 fish oil using our technology compared to standard omega-3 fish oil demonstrated an increase of 567% in peak blood levels. The relative bioavailability calculated using the area under the curve was also increased by 487%.

QH Ubiquinol

A pharmacokinetic study comparing Kaneka QH™ Ubiquinol formulated with our technology to standard Kaneka QH™ Ubiquinol demonstrated an increase of 696% in peak blood levels of Ubiquinol. The relative bioavailability calculated using the area under the curve was also increased by 485%.

Polymethoxylated Flavones (PMF)

In a pharmacokinetic study, we improved the bioavailability of Nobiletin and Tangeretin as well as its metabolites. The relative bioavailability of Nobiletin increased by 288% while the peak plasma levels (Cmax) of Nobiletin, Tangeretin, and their metabolites were increased up to 800%.

Cannabinoids

A pharmacokinetic study (single oral dose, crossover) in humans comparing Cannabidiol (CBD) formulated using our technology to the same Cannabidiol in a different emulsion demonstrated an increase of absorption in peak blood levels. The relative bioavailability of a single oral dose of Cannabidiol was asserted using the AUC. The results showed xxx% higher bioavailability in our formulation compared to the other formula.

And much more ...

VESIsorb® has been successfully applied to more than 50 of the most popular, science-backed ingredients and proprietary formulas like like concentrated omega-3 EFAs, coenzyme Q10, QH ubiquinol Q10, vitamin K2, curcumin, phytocannabinoids, vitamin D, pterostilbene, palm tocotrienols, diindolylmethane (DIM), gamma tocopherols, citrus polymethoxylated flavones (PMFs), resVida®, resveratrol, krill oil, algal DHA, vitamin A (retinoids), phospholipids and beta-caryophyllene, among others.
«
Back
Next
»

Medical Devices

Coenzyme Q10

A pharmacokinetic study (single oral dose, crossover) in humans comparing Coenzyme Q10 formulated using our technology to standard Coenzyme Q10 in different formulations demonstrated an increase of absorption in peak blood levels. The relative bioavailability of a single oral dose of 120mg of Coenzyme Q10 was asserted using the AUC. The results showed 622% higher bioavailability in our formulation compared to the oil-based formula and 499% higher bioavailability compared to the solubilizate.

Omega-3

A pharmacokinetic study comparing omega-3 fish oil using our technology compared to standard omega-3 fish oil demonstrated an increase of 567% in peak blood levels. The relative bioavailability calculated using the area under the curve was also increased by 487%.

QH Ubiquinol

A pharmacokinetic study comparing Kaneka QH™ Ubiquinol formulated with our technology to standard Kaneka QH™ Ubiquinol demonstrated an increase of 696% in peak blood levels of Ubiquinol. The relative bioavailability calculated using the area under the curve was also increased by 485%.

Polymethoxylated Flavones (PMF)

In a pharmacokinetic study, we improved the bioavailability of Nobiletin and Tangeretin as well as its metabolites. The relative bioavailability of Nobiletin increased by 288% while the peak plasma levels (Cmax) of Nobiletin, Tangeretin, and their metabolites were increased up to 800%.

Cannabinoids

A pharmacokinetic study (single oral dose, crossover) in humans comparing Cannabidiol (CBD) formulated using our technology to the same Cannabidiol in a different emulsion demonstrated an increase of absorption in peak blood levels. The relative bioavailability of a single oral dose of Cannabidiol was asserted using the AUC. The results showed xxx% higher bioavailability in our formulation compared to the other formula.

And much more ...

VESIsorb® has been successfully applied to more than 50 of the most popular, science-backed ingredients and proprietary formulas like like concentrated omega-3 EFAs, coenzyme Q10, QH ubiquinol Q10, vitamin K2, curcumin, phytocannabinoids, vitamin D, pterostilbene, palm tocotrienols, diindolylmethane (DIM), gamma tocopherols, citrus polymethoxylated flavones (PMFs), resVida®, resveratrol, krill oil, algal DHA, vitamin A (retinoids), phospholipids and beta-caryophyllene, among others.
«
Back
Next
»

Longstanding Global Partnership

In 2005, Vesifact and SourceOne Global Partners (Chicago, IL USA) formed a strategic alliance with the vision to bring new levels of bio-enhanced formulas to the natural products industry. SourceOne, a leading provider of health and wellness solutions, serves as the exclusive worldwide distribution and marketing partner for Vesifact technologies, trademarked VESIsorb®. In 2018, Vesifact and SourceOne launched Geocann (Fort Collins, CO USA), an organization that manages the global distribution and marketing for cannabis applications.

Click here to visit the SourceOne Global Partners website.
Click here to visit the the Geocann website.
Click here to visit the VESIsorb website.

Take a look inside Vesifact

A message from our CEO

Vesifact has an excellent team with many members serving more than 20 years. It gives me great pride knowing that my father and I were able to build a competitive infrastructure with scientists, researchers and product developers that hold the highest level of technical expertise.
Marc Weder
CEO & co-founder
Send us a message.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Site Address
Vesifact AG
Technology Transfer
Prof. Dr. H.G. Weder
Joechlerweg 4
6340 Baar, Switzerland

47° 12’ 1.16” N, 8° 31’ 33.2” E (WGS84)
Postal Address
Vesifact AG
Technology Transfer
Prof. Dr. H.G. Weder
P.O. Box 1734
6341 Baar, Switzerland